Golden Helix Inc.

Company Snapshot

Founded: 1998
Entity Type: Private
Region: U.S.
Headquarter: U.S.
Key Geographics: U.S., Japan
Corporate Address: 1487 North 14th Avenue Bozeman Montana 59715 U.S. Tel. +1-406-585-8137 www.goldenhelix.com

Company Overview

Golden Helix has been delivering bioinformatics solutions for the advancement of translational medicine and life science research for over 20 years. The firm’s innovative technologies and analytic services empower healthcare professionals and scientists at all levels to derive meaning from the rapidly rising volumes of genomic data produced from microarrays and NGS. With these solutions, hundreds of the world’s top biotech, pharmaceutical and academic research organizations can harness the full potential of genomics to know the cause of disease, improve the safety and efficacy of drugs, develop genomic diagnostics and advance the quest for personalized medicine. The company products and services have been cited in around 1,000s of peer-reviewed publications.

Golden Helix offers the following bioinformatics products for clinical applications: VarSeq (variant analysis software for gene panels, exomes and whole genomes); VSClinical (clinical interpretation of variants); VS-CNV (direct calls of CNVs in targeted regions); VSPipeline (clinical workflow for CLIA and CAP certified analysis); VSReports (customized clinical report of analysis data); and VSWarehouse (a warehouse for NGS variant call sites, clinical reports and catalogs of variant assessments).

Golden Helix Inc. In Reports

Global DNA Sequencing: Research, Applied and Clinical Markets

BCC Research Market Report for DNA Sequencing Industry. Global market for DNA sequencing technologies and their applications in research, applied and clinical segments.

Rare Disease Diagnostics: Technologies and Global Markets

Explore the rare disease diagnostics, including the DNA sequencing industry, PCR industry, laboratory services industry, etc.

Global DNA Read, Write and Edit Market

The global market for DNA read, write and edit applications should grow from $17.0 billion in 2019 to $43.1 billion by 2024 with a compound annual growth rate of 20.5% during the period of 2019-2024.

Company's Business Segments

  • Bioinformatics Solutions : The company provides software for healthcare professionals and scientists at all levels to analyze and interpret NGS data efficiently and effectively.

Applications/End User Industries

  • Commercial Testing Labs
  • Hospital Labs
  • Human Genetic Research
  • Country-Wide Genome Projects
  • Pharmaceutical R&D
  • GWAS Research